BENLYSTA (also known as Belimumab)
Benlysta is antibody that binds and inhibits B-cell activating factor. Benlysta essentially targets overproduction of B-cells, which is central to the autoimmune processes like Lupus.
Patients with active systemic lupus erythematous who are already receiving standard therapy.
Benlysta has not been studied in patients with severe active lupus nephritis or severe active central nervous system lupus.
Benlysta is administered as an infusion every 2 weeks for the first 3 doses and every 4 weeks thereafter.